Dr Nick Coupe

Dr Nick Coupe
Nick
Coupe
B.Med Sci, MBBS (Hons), FRACP, MRCP, DPhil, Consultant Medical Oncologist

Languages spoken

English

Expert in

chemotherapy, targeted therapies and immunotherapies for the treatment of lung cancer and melanoma

Interested in

Immunotherapy for the treatment of lung cancer and melanoma, early and late phase clinical trials, teaching, education supervision for trainees

Overview

Centres

Oxford
Oxford

Peters Way, Sandy Lane West, Oxford, OX4 6LB

51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford
+44 (0)1865 237 700
mediahawkNumber3680 mhMobile

Specialises in

Lung cancer
Condition
Condition/Cancer
Condition/Cancer/Lung cancer
Skin cancer
Condition
Condition/Cancer
Condition/Cancer/Skin cancer

Treatments

Chemotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Chemotherapy
Immunotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Immunotherapy

After competing his medical and oncology training in Sydney, Dr Nick Coupe moved to Oxford to undertake a fellowship in early phase clinical trials. Here he developed an interest in skin cancer.

Dr Coupe was awarded a CRUK fellowship and subsequently completed a PhD within the University of Oxford investigating associations between a melanoma and the process of tumour driven new blood vessel formation (angiogenesis). He was formally accepted onto the GMC specialist register in 2019 and obtained a substantive position at the Churchill Hospital as a consultant medical oncologist the same year, specialising in melanoma and lung cancer.

Dr Coupe has considerable experience in chemotherapy, targeted therapies and in particular, immunotherapies for the treatment of lung cancer and melanoma.

Dr Coupe is actively involved in clinical research, as a principal investigator of a number of clinical trials at the Churchill site. He has multiple publications (listed below) and is also interested in teaching and trainee supervision.

Career positions

Current position(s)

  • Consultant Medical Oncologist, Oxford

Education

Current position(s)

  • Medical and oncology training, Sydney University
  • Fellowship in early phase clinical trials, Oxford

Professional memberships

  • General Medical Council
  • Royal Australasian College of Physicians
  • Royal College of Physicians

Accomplishments

Awards

  • Department of Oncology Clinical Research Training Fellow (phD) prize winner, 2017
  • CRUK funded Clinical Training Research Fellowship, 2015
  • Oxfordshire Health Services Research Committee (OHSRC) competitive research grant
  • John Harris Prize, Sydney University
  • Albert Hing Memorial Prize in Gynaecology, Sydney University

Publications & affiliations

  1. Fane M, Ecker B, Kaur A, Marino G, Alicea G, Coupe N, Douglass S, et al. sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clin Cancer Res. 2020 Nov 1;26:5709–19.
  2. Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125(1):99–108.
  3. Manoharan V, Lee S, Chong S, Yap J, Coupe N, Wilson R, et al. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy. Ann Nucl Med. 2017 May;31(4):315–23.
  4. Lloyd-Lavery A, Hodgson T,Coupe N, Bond S, Shah K, Espinosa O, Payne MJ, Middleton MR, Matin RN. Delayed oral toxicity from long-term vemurafenib therapy. Br J Dermatol. 2016 May;174(5):1159-60
  1. Coupe N, Gupta A, Lord SR. Early phase cancer clinical trials: design, ethics and future directions. Br J Hosp Med (Lond). 2015;76(7):409-13
  1. Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, et al. PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Eur J Cancer. 2015;51(3):359-66